ROCKVILLE, Md.--(EON: Enhanced Online News)--Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, announces two additions to their Scientific Advisory Board.
“We could not be more pleased to have in place a Scientific Advisory Board with such exceptional and varied experience in the field of immunotherapy and the life sciences”
“We could not be more pleased to have in place a Scientific Advisory Board with such exceptional and varied experience in the field of immunotherapy and the life sciences,” stated Immunomic CEO, Dr. William Hearl. “Our new additions ensure the LAMP-Vax technology platform is poised for success as we continue to apply the DNA vaccine in oncology.”
New members of the Immunomic Scientific Advisory Board:
Peter C.R. Emtage, Ph.D., is adept in managing successful immunotherapy programs focused on oncology. Dr. Emtage currently serves as Chief Scientific Officer at Cell Design Lamps, Inc. (CDL). Prior to joining CDL, he was Vice President of Synthetic Immunology at Intrexon Corporation and was Vice President of Immune Mediated Therapy in the Oncology Innovative Medicines group at Medimmune. At Medimmune, Dr. Emtage designed and implemented a comprehensive immune therapy cancer strategy. He has over sixteen years of biologics development experience in the fields of oncology, autoimmunity, infectious diseases, and inflammation. Dr. Emtage holds a B.S. and M.S. in Molecular Biology and Genetics from the University of Guelph and received his Ph.D. in Molecular Virology, Immunology and Inflammation at McMaster University. At the beginning of his career, he also was a post-doctoral fellow at the National Institutes of Health and held roles at Aventis Pasteur and Harvard Medical School.
Robert Hamilton Pierce, M.D., is experienced in managing large teams dedicated to developing disease-oriented and tissue-based translation medicine platforms. Dr. Pierce recently was appointed as a Member of the Fred Hutchinson Cancer Research Center and the Scientific Director of the Immunopathology Lab. Previously, he was the Chief Scientific Officer (CSO) of OncoSec Medical Incorporated. Prior to joining OncoSec, Dr. Pierce was at Merck Research Labs, contributing to multiple successful immunology and oncology IND applications. Most notably, Dr. Pierce was a key member of the MK-3475 (pembrolizumab) project team and was instrumental in the development of biomarker approaches to defining response and non-response phenotypes to anti-PD1 blockade, including the 22C3 PD-L1 companion diagnostic IHC assay. He also participated in the design of two Phase 2 anti-PD-1 (MK-3475) oncology studies in collaboration with CITN, the Cancer Immunotherapy Trials Network. Dr. Pierce is a graduate of Yale College and Brown University School of Medicine. Following graduation from medical school, he completed a residency program in Anatomic Pathology and a post-doctoral research fellowship at the University of Washington in Seattle, WA.
The Scientific Advisory Board also includes Shan Lu, M.D., Ph.D., Professor of Medicine, University of Massachusetts Medical School; Jennifer Harris, Ph.D., PharmD; Peter Creticos, M.D., Associate Professor of Medicine at John Hopkins University; Thierry Olivry, DrVet, Ph.D., DipECVD, DipACVD, Professor of Dermatology at NC State University Vet School; and Lisa Beth Ferstenberg, M.D.
Immunomic Therapeutics, Inc. is a privately-held, clinical stage biotech company on a mission to pioneer vaccines that transform lives. The company, based in Rockville, MD, is developing nucleic acid vaccines based on the patented Lysosomal Associated Membrane Protein (LAMP) Technology. Termed LAMP-Vax™, the exclusive immunotherapy technology works with the body’s natural biochemistry system and has the potential to improve a broad range of vaccines. ITI entered into a licensing agreement with Astellas Pharma Inc. in 2015 to explore the use of LAMP-Vax in the prevention and treatment of allergic diseases, and is now focused on cancer immunotherapy. The LAMP platform has been tested in Phase I and II clinical studies. For more information, please visit www.immunomix.com.